arrow
S

Sébastien Salas

la timone university hospital of marseille
H指数:42
被引数:6,877

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Droplet Digital PCR Assessment of MDM2 Amplification in Liposarcoma Diagnosis and Prognosis: A French Single-Center Cohort Study

脂肉瘤诊断和预后中MDM2扩增的数字液滴PCR评估:一项法国单中心队列研究

2026-08-130
OA
Characteristics and outcome of intra-abdominal desmoid-type fibromatosis

腹内型硬纤维瘤的特征和预后

2026-05-190
PRE
Corrigendum to “Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)”

“索拉非尼在局部晚期和转移性脊索瘤患者中的应用: 法国肉瘤组 (GSF/GETO) 的II期试验”

2025-10-150
PRE
Outcome of 1773 superficial non-dermatofibrosarcoma sarcomas A French Sarcoma Group study (FSG) from the NETSARC database

1773例非皮肤纤维肉瘤浅表肉瘤的结局:一项来自NETSARC数据库的法国肉瘤组(FSG)研究

2025-09-120
PRE
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

6年与3年伊马替尼辅助治疗局部GIST复发风险高的患者的随机研究

2024-12-016
OAAI
Therapeutic strategy for advanced stages salivary carcinomas of the tongue: A multicenter REFCOR study
2024-12-010
OAAI
Immunoscore-IC predicts nivolumab efficacy as adjuvant treatment after salvage surgery in head and neck cancer squamous cell carcinoma: The ADJORL1 trial

Immunoscore-IC预测头颈鳞状细胞癌挽救性手术后辅助治疗中使用nivolumab的疗效:ADJORL1试验

2024-09-010
PRE
Long circulating-free DNA fragments predict early-progression (EP) and progression-free survival (PFS) in advanced carcinoma treated with immune-checkpoint inhibition (ICI): A new biomarker

循环游离DNA片段可预测接受免疫检查点抑制治疗的晚期癌患者的早期进展(EP)和无进展生存期(PFS):一种新的生物标志物

2024-09-010
PRE
Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab (D) combined with weekly paclitaxel carboplatin in 1st-line in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible to cisplatin

多中心II期FRAIL-IMMUNE试验结果,评估了度伐利尤单抗(D)联合每周给药的紫杉醇卡铂在一线治疗中,对于不符合顺铂使用条件的复发性/转移性头颈鳞状细胞癌(R/M SCCHN)患者的有效性与安全性。

2024-09-010
PRE
Improved nationwide survival of sarcoma patients with a network of reference centers
2024-04-019
OA
Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers
2023-09-016
PRE